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Abstract 
 
Objectives: There have been a numerous initiatives in Azerbiajan in recent years to improve  
antibiotic utilization including educational programmes among patients, pharmacists and physicians. 
This study aimed to analyse the influence of these multiple initiatives on antibiotic utilization as a 
basis for suggesting future initiatives.  
 
Methods: Observational retrospective study of total antibiotic utilization from 2011 to 2015 based on 
import data. The quality of aggregated antibiotic prescribing was assessed against recognised 
indicators including those of  WHO Europe, as well as compared to neighbouring countries as 
reference points.  
 
Results: There was a significant reduction in total antibiotic utilization from 17.1DIDs in 2011  in 
Azerbaijan to 8.02 DIDs in 2015, the lowest level compared with similar countries. Beta lactam 
antibiotics were typically the largest group of antibiotics with low overall use of co-amoxiclav (although 
relative utilisation rising), macrolides, cephalosporins and fluoroquinolones. There are concerns with 
rising use of tetracyclines in recent years in place of penicillins with changing pricing policies, as well 
as high relative use of third generation cephalosporins.  
 
Conclusions: Multiple interventions in Azerbaijan in recent years appear to have resulted in low use 
of antibiotics when compared with similar countries. However, there are some concerns especially 
with third generation cephalosporins. There needs to be a closer look at indications to further improve 
antibiotic use. 
 
Key words: antibiotic utilization; antibiotic resistance; Azerbaijan; policy initiatives; quality indicators 
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1. Introduction 
 
There are increasing concerns with the growing rates of antimicrobial resistance (AMR) across 
countries (1-3), with the resultant implications on morbidity, mortality and costs within countries. As a 
result, AMR has become one of the biggest public health challenges world-wide, with estimated 
deaths due to AMR reaching 444 million by the 2050 (4, 5), and estimated costs of ¼ELOOLRQSHU\HDU
in Europe or higher (1, 2).  
 
The occurrence and spread of AMR appears to correlate with increasing and irrational use of 
antibiotics (6-8). This includes the self-purchasing of antibiotics across countries, including European 
countries, which is typically for viral infections such as upper respiratory tract infections (URTIs) (9-
18),  with URTIs the predominant infection seen by physicians in ambulatory care (16).  
 
Currently in Azerbaijan, patients need a prescription to be dispensed an antibiotic as it is illegal for 
pharmacists to dispense antibiotics without a prescription. However, there has been variable 
enforcement of this law to date. This is not helped by the fact that patients in Azerbaijan typically 
having to cover the full cost of antibiotics themselves, even if they are prescribed by a physician. 
Consequently, it does not matter to them if the cost of the medicine is the same, and may even save 
on physician fees as patients must typically pay to see a physician. In addition, pharmacists may 
make a greater profit from dispensing an antibiotic rather than a OTC medicine such as paracetamol 
for a temperature associated with a viral infection. This though is beginning to change with greater 
scrutiny over pharmacy dispensing practices with penalties for abuse (Table 1). There are though 
exemptions to 100% co-payment. These include patients with AIDs and HIV, where treatment is 
funded via the Global Fund, patients with diabetes as well as patients with tuberculosis (TB) .  Having 
said ths, there have been many activities over the years, especially in recent years, among all key 
stakeholder groups to encourage rational prescribing and dispensing of antibiotics in Azerbaijan. 
 
As a result of the various initiatives in recent years (Table 1), Azerbaijan in 2011 had the second 
lowest consumption of antibiotics among non-European Union (EU) southern and eastern European 
countries, and newly independent states, at 17.1 DIDs (DDDs per one thousand inhabitants per day), 
approximately half the rate seen in Turkey (8). Encouragingly, Azerbaijan had the second highest use 
of beta lactam antibiotics as a percentage of total of antibiotic use, with a correspondingly low use of 
co-amoxiclav (0.3DIDs), low use of cephalosporins, as well as low use of fluorquinolones. There was 
also low use of long-acting macrolides (azithromycin) in Azerbaijan versus other European countries 
(8).  
 
However, it is important to see whether there is continued low, or even lower, use of antibiotics in 
Azerbaijan in recent years as well as continued low use of co-amoxiclav, cephalosporins and the 
fluorquinolones. High utilisation of co-amoxiclav increases side-effects from antibiotics, as well as 
resistance, resulting in co-amoxiclav typically recommended as second line after amoxicillin (19-23). 
There are also concerns with increasing use of cephalosporins, increasing resistance rates, rates of 
C. difficile, cardiac and other side-effects, as well as increasing the use and resistance to the 
fluoroquinolones (23-26). In addition, the WHO identified the fluoroquinolones, third- and fourth-
generation cephalosporins, macrolides and glycopeptides as being of the highest priority for risk 
management to improve future use (23). 
 
There is also a need to record what reforms and initiatives have been instigated in Azerbaijan over 
the years to influence antibiotic utilisation. This is seen as particularly important to provide guidance to 
other similar countries that have higher use of antibiotics as well as concerns with high use of co-
amoxiclav, cephalosporins and fluoroquinolones.  
 
We are aware that conditions such as childhood diarrhoea are an issue in Azerbaijan leading to 184 
deaths per 100,000 children under five years, which is over twice the global average (27). However, 
targeted interventions including sanitation, nutrition, and hydration, have a greater influence on 
reducing mortality although antibiotics are indicated in certain situations (27-29). In addition, 
Azerbaijan ranks 78th out of 188 countries in their achievement of Sustainable Development Goals, 
higher than Turkey, Uzbekistan, Moldova, Macedonia and Serbia (30), due to issues of childhood 
diseases, tuberculosis, high alcohol use, and the rise in non-communicable diseases (30), However, 
some of these issues are not necessarily related to antibiotic use. 
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Consequently, the aim of this paper is to present and analyse total antibiotic consumption in 
Azerbaijan in recent years alongside ongoing initiatives to improve antibiotic use and reduce AMR. 
Subsequently, compare the findings with other similar European countries and former Soviet Union 
Republics to review potential additional measures that could be instigated in Azerbaijan if needed, as 
well as provide possible exemplars.  
 
2. Methodology 
 
This was a retrospective observational study of total antibiotic consumption in Azerbaijan from 2011 to 
2015 based on import data. Import data on antimicrobials is provided each quarter by the wholesalers 
in Azerbaijan, with currently no breakdown by physician or pharmacist. Exact consumption data is 
currently only available for patients with HIV and TB as these medicines are provided free of charge. 
 
Total antibiotic consumption was recorded as it is difficult to currently break these figures down into 
component parts within Azerbaijan. However, this is similar to surrounding European countries and 
former Soviet Union Republics (23). 
 
The collection and analysis of data on drug consumption was undertaken using the ATC (Anatomical 
Therapeutic Chemical classification)/DDD (defined daily dose) methodology, with DDDs defined as 
the amount of the drug most commonly used in adults for the most common indication (8, 31, 32).  
Utilisation data was further expressed in DIDs to compare utilisation rates across countries with 
different population sizes, similar for other diseae areas (8, 31, 33, 34). 
 
Key measures used to examine trends over time included relative consumption measures, expressed 
as a percentage of total consumption as well as specific antimicrobial agents within a class (23).  The 
quality of antibiotic prescribing was assessed using the European Surveillance of Antimicrobial 
Consumption (ESAC), European Centre for Disease Prevention and Control (ECDC) and WHO 
quality indicators (8, 23, 35, 36). These included:  
x Total utilisation of antibiotics expressed as DIDs 
x Utilisation of penicillins (J01C) in DIDs and as a % of total antibiotic use 
x % utilisation of combination penicillins such as co-amoxicav as a percentage of amoxycillin use 
x Total utilisation of cephalosporins ((J01D) in DIDs and as a % vs. total antibiotics 
x % utilisation of third- and fourth-generation cephalosporins vs first and second generation 
cephalosporins 
x Total utilisation of macrolides (J01F) in DIDs and as a % vs. total antibiotics 
x Utilisation of quinolones (J01M) expressed in DIDs as well as % vs. total antibiotic use 
 
We did not specifically review the utilisation of tetracylines as a quality indicator since, as mentioned, 
the WHO identified the fluoroquinolones, third- and fourth-generation cephalosporins, macrolides and 
glycopeptides as being of the highest priority for risk management to improve future use (23). 
 
The findings in Azerbaijan were also compared to surrounding European countries and former Soviet 
Union Republics in 2011 and 2014 based on available data (8, 23), as well as European countries, 
especially Eastern European countries in the ECDC network in 2015 (36). These will be used to 
suggest additional measures within Azerbaijan to further improve the utilisation of antibiotics if 
pertinent acknowledging that we did not link antibiotic use to specific indications. 
 
Since multiple initiatives and reforms were instigated over time with varying intensity, coupled with the 
problems with import data and their monthy fluctuations, it was impossible to undertake sophisticated 
statistical analyses such as time series analyses. As a result, more simple statistical tests, including 
trend analyses where possible, were performed to assess the level of significance, with significance 
seen as p <0.05. This is similar to other health authority analyses where multiple interventions are 
conducted over time with no opoortunity for time series analyses (33, 37-39).   
 
No ethical approval was sought as this is a retrospective study of aggregated drug utilisation data. 
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3. Results  
 
There have been various ongoing initiatives and measures in Azerbaijan over the years to try and 
improve antibiotic utilisation. These are captured in Table 1 building on initiatives in other countries (9, 
40, 41). 
 
Table 1 ± Details of multiple ongoing reforms and initiatives in Azerbaijan in recent years to improve 
antibiotic utilisation 
 
Key stakeholders Activities 
Physicians x Orchestrated government (Ministry of Health and others) initiatives in 
April and November each year nationwide over the past years aimed at 
physicians and other key stakeholder groups to preserve antibiotics, 
e.g. not to over use antibiotics for viral infections. This includes a 
variety of approaches including educational workshops with physicians, 
leaflets, TV and other multimedia campaigns for patients and 
pharmacists 2 to 3 times a year based on WHO approaches  
x For physicians, this includes educational activities 2 to 3 times a year 
to improve their knowledge of different treatment approaches 
especially for common infections in the community during the year (in 
addition to orchestrated activities in April and November) 
x This also includes recommended antibiotics for infections such as 
upper respiratory tract infections including penicillins first line. In 
addition, advocating narrow vs. broad spectrum antibiotics where 
pertinent. This also includes targeting ceftriaxone in recent years given 
concerns with increasing unjustified utilisation through educational 
workshops coupled with printed leaflets for physicians 
x Activities in November include a week of awareness about antibiotics 
as part of Antibiotic Awareness week. This includes multiple seminars 
between physicians and employees of the Ministry of Health to reduce 
inappropriate antibiotic prescribing.  
x New clinical protocols are currently being planned in Azerbaijan with 
increasing control over the prescribing and utilisation of antibiotics 
x Instigation of compulsory INN prescribing similar to other countries, 
e.g. Abu Dhabi and Lithuania[40, 41]]. The objective being to reduce 
the marketing influence of pharmaceutical companies  
Pharmacists x Educating pharmacists nationwide that it is illegal to sell antibiotics 
without a prescription with inspectors regularly visiting pharmacists to 
monitor self-purchasing levels (as this still occurs) in addition to 
assessing the quality of medicines dispensed. This is undertaken 
during unscheduled and planned inspections of pharmacies by Ministry 
of Health officials to check them and educate pharmacists, i.e. in 
addition to quality checks on the medicines dispensed, checking 
prescription forms and monitoring the release of prescription drugs. 
Pharmacists are also remined about pertinent legislative acts and 
penalties for their violation to help reduce illegal selling of antibiotics 
x Included in the general campaigns in April and November (this includes 
antibiotic awareness week) as part of the drive to address self-
purchasing by educating pharmacists (and patients). This includes 
emphasising that most infections they see are typically viral in origin so 
do not require an antibiotic 
x It is likely that fines will start to be applied in Azerbaijan for illegal 
selling of antibiotics without a prescription, similar to other countries in 
the WHO Region such as the Republic of Srpska, Montenegro and 
Turkey [9] 
Patients x A key part of the general campaigns in April and November to try and 
reduce requests to physicians and pharmacists for antibiotics 
especially for suspected viral infections, which includes the majority of 
infections seen in ambulatory care 
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x In 2014 ± there was also a new pricing regulation to help reduce the 
costs of medicines to patients. Included within this was reference 
pricing within 5 categories. This reduced the number of manufacturers 
as well as available choices. In addition, reducing marketing activities 
among pharmaceutical companies 
x There are also further planned initiatives to enhance awareness of the 
dangers of inappropriate use of antibiotics among the public to reduce 
self purchasing of antibiotics and strengthen the message that 
antibiotics are only available via physicians. This will include 
multimedia campaigns 
 
With respect to the new pricing regulation in 2014 (Table 1), the Tariff Council now regulates 
wholesale and retail prices for all registered medicines based on competition and other factors. As 
indicated, all registered medicines have now been divided into 5 groups depending on the 
manufacturing country as Azerbaijan is an import-dependent country with very limited production of 
medicines. After the price adjustments, wholesalers and companies cannot sell medicines at the price 
they wish as there are now large fines if the pharmacy (via the wholesalers) sell medicines to patients 
not at regulated prices. This has appreciably reduced the profitability of companies. As a result, a 
number of companies have left the pharmaceutical market in Azerbaijan. However, lower prices can 
benefit patients. This has meant some antibiotic classes have lower prices than before such as the 
tetracyclines.   
As a result, there has been a steady decline in total antibiotic consumption in Azerbaijan in recent 
years, which has reached significance when total use is combined (Table 2).  
 
Table 2 - Total consumption of J01 antibacterials by pharmacological subgroup (DIDs) in Azerbaijan 
 
Antibiotic 2011 2012 2013 2014 2015 p-vlaues  
Tetracyclines (J01A) 1.4 2.2 0.8 0.6 1.81 P=0.76 
Beta lactams (J01C) 11.3 13.8 6.6 5.6 1.99 P=0.03 
Cephalosporins (J01D) 0.8 0.7 0.5 0.5 0.73 P=0.51 
Sulfonamides and trimethoprim 
(J01E) 0.8 0.3 0.9 0.5 0.7 
P=1 
Macrolides, lincosamides and 
streptogramins (J01F) 1 1.3 0.9 0.6 1 
P=0.45 
Quinolone antibacterials (J01M) 0.8 1 0.7 0.4 0.84 P=0.54 
Others 1.0 1.2 1.3 0.3 0.95 P=0.49 
Total 17.1 20.5 11.7 8.5 8.02 P=0.05 
 
Figure 1 provides relative consumption data in percentages compared with total antibiotic utilisation, 
showing increasing use of tetracyclines, macrolides, and fluoroquinolones in 2015 with lower use of 
beta-lactam antibiotics. Within the amoxycillins (J01C), there has been growing use of co-amoxiclav in 
recent years as a percentage of total amoxycillin alone or in combination (Table 3). However, 
absolute usage has remained at 0.2 to 0.4 DIDs over time, with the increasing percentage a factor of 
declining amoxycillin use (Figure 1). 
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Figure 1 - Relative consumption (%) of J01 antibacterials by pharmacological subgroup 
 
 
Table 3 - Relative consumption of amoxicillin, amoxicillin and clavulanic acid 
 
Antibiotic percentages and DIDs 2011 2012 2013 2014 2015 
Amoxicillin (J01CA04) 93% 94% 84% 57% 64% 
Amoxicillin and clavulanic acid 
(J01CR02) - DIDs and % 0.3 - 7% 0.2 - 6% 0.2 - 16% 0.2 - 43% 0.4 - 36% 
Total (DIDs) 4.4 3.5 1.5 0.5 1.1 
 
There has been relatively low use of the cephalosporins over the study period versus other antibiotics 
(Figure 1); however typically this is third generation cephalosporins (Figure2). Figure 3 provides a 
comparison between total utilisation of antibiotics in Azerbaijan in 2014 and 2015 versus neighbouring 
former Soviet Union Republics and Central and Eastern European countries.  
 
Figure 2 - Relative consumption of cephalosporins by generation (percentages of total cehalosporin 
use that year) 
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Figure 3 ± Comparison of total antibiotic utilisation in Azerbaijan with selected neighbouring countries 
 
 
 
 
 
Figure 4 - Comparison of beta lactam antibiotic utilisation in Azerbaijan with selected neighbouring 
countries 
 
 
Figure 4 provides a similar comparison for beta lactam antibiotic (J01C)s, Figure 5 for macrolides 
(J01F) and Figure 6 for the quinolones (J01M). 
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Figure 5 - Comparison of macrolide utilisation in Azerbaijan with selected neighbouring countries 
 
 
 
Figure 6 - Comparison of quinolone utilisation in Azerbaijan with selected neighbouring countries 
 
 
 
 
4. Discussion  
 
It was encouraging to see a significant decline in the total antibiotic use in Azerbaijan in recent years 
(Table 2), potentiallyt helped by the ongoing multiple and intergrated initiatives in Azerbajian, targeting 
all key stakeholders to moderate the prescribing and dispensing of antibiotics (Table 1). This appears 
similar to the findings of other studies regarding anti-infectives, and other disease areas, where 
multiple interventions have improved the rational use of medicines (33, 34, 37, 38, 42). However, we 
cannot say this with certainty in this research due to the limitations of available data. 
 
Overall, there was relatively low utilisation of antibiotics within Azerbajian, which compares favourably 
with other European countries and former Soviet Union Republics  (Figure 3)(23).(36).  
 
The high use of beta lactam antibiotics as a percentage of total antibacterial use at 65.6% in 
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former Soviet Union Republics in 2014 (Figure 4) (23). However, there was a change in 2015, with 
utlilisation of penicillins decreasing as a percentage of total utilisation in Azerbaijan at 24.8% (Table 2, 
Figure 1). This compares with Germany but lower than Estonia, Latvia, Croatia, and Slovenia in 2015 
(Figure 4) (36) . This appreciable decrease in the use of penicillins, with a corresponding increase in 
the utilisation of tetracyclines (Tables 2, Figure 1), may well be the result of the changes in the prices 
of pharmaceuticals following the reforms in 2014 and a number of companies no longer marketing 
their products (Table 1). This will be investigated further with concerns that penicillins are not being 
routinely used first line in for instance for suspected bacterial URTIs, which tend to be the commonest 
infections in ambulatory care (7, 16).  
 
There was typically low use of co-amoxiclav throughout the study period in terms of DIDs (Table 3). 
However, the percentage versus total amoxycillins has been rising in recent years with 43% in 2014, 
which is high versus Tajikistan (2%) and Uzbekistan (12%), but similar to Albania (37%) and 
Kyrgyzstan (49%) and lower than Turkey (89%) in 2014 (23). Again, this will be investigated further. 
However, this is likely to be more a phenomenon of reduced amoxycillin use rather than appreciably 
increasing co-amoxiclav use given typically low utilisation, although rising in 2015 versus 2014 (Table 
3).  
 
Whilst overall utilisation of the cephalosporins has remained relatively low in Azerbaijan at 6% of total 
antibiotic utilisation in 2014 (Figure 1) versus other former Soviet Union countries  (23), there is 
concern with high utilisation of third generation cephalosporins in 2014 (Figure 2). This compares with 
only 16% in Serbia and 30% in Albania, but similar to 74% in Armenia and lower than 83% in 
Tajikistan in 2015 (23). Ceftriaxone is typically promoted by pharmaceutical companies as a 
convenient and effective cephalosporin (via personal communication), which we believe resulted in its 
high use among the cephalosporins over the years (Figure 2). Further educational campaigns (Table 
1) are now being implemented promoted by the Ministry of Health to try and reverse this high 
utilisation of ceftriaxone in favour of first and second generation cephalosporins. This is alongside 
measures to further regulate prices of the cephalosporins to increase the use of first and second 
generation cephalosporins at the expense of ceftriaxone. The impact of these initiatives will be 
explored further in future research projects.  
 
There was also low use of the macrolides and other J01F antibiotics in Azerbaijan in 2014 at just 0.6 
DIDs (Table 2, Figure 1). This compares favourably with other former Soviet Union Republics (Figure 
5) (23), as well as other Central and Eastern European countries (36). Utilisation rates will be 
monitored given the rise in utilisation in 2015 versus 2014. This again may be the result in the 
changes in the pricing policies for antibiotics in 2014. 
 
Encouragingly, there was also low use of fluoroquinolones in Azerbaijan at 0.4DIDs in 2014 (Table 2, 
Figure 1) versus other former Soviet Union Republics (Figure 6) (23),   as well as other Central and 
Eastern European countries (36). This again may well have been helped by educational campaigns 
especially among physicians (Table 1). 
 
The planned introduction of electronic prescribing recording the prescribing and dispensing of 
antibiotics in ambulatory care should help to further improve antibiotic utilisation in Azerbaijan. This 
will include greater scrutiny over any self-purchasing of antibiotics as well as the potential introduction 
of quality and other indicators to improve future use. However, any introduction of quality indicators 
must be based on greater knowledge of the indications for current prescribing as well as greater 
knowledge of resistance rates, morbidity and mortality due to infectious diseases in Azerbaijan. This 
especially as there has been a marginal rise in deaths due to infection and parasitic diseases in 
Azerbaijan in recent years, rising from 472 in 2014, to 510 in 2015 and 564 in 2016 (43).  In addition, 
investigating further issues of affordability regarding antibiotic use, especially if this deters the 
purchasing of antibiotics where there are appropriate indications adversely affecting patients. These 
are projects for the future along with the forthcoming instigation of a National Action Plan (NAP) to 
combat resistance to antimicrobials and its potential impact. The NAP will include greater knowledge 
of current resistance rates to guide additional activities. 
 
There also needs to be initiatives to reduce the influence of pharmaceutical companies and their 
marketing (Table 1), which can  build on recent initiatives to enhance INN prescribing as well as 
further manipulate prices (Table 1).We will be monitoring these developments as well in the future.  
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5. Limitations 
 
We acknowledge that there are several limitations with this study. Firstly, there can be unreliability 
with measuring utilisation via import data. However, the relative percentages and their comparisons 
with other similar countries provide guidance for the future in Azerbaijan and surrounding countries. 
Secondly, there is no data regarding accessability, availability or affordability of antibiotics and these 
issues could well have also influenced antibiotic consumption. Thirdly, there were no indicators of 
prescribing quality in relation to any diagnoses within the available data sets, and no data currently on 
resistance patterns to also assess appropriateness. Lastly, we are unable to comment on any 
changes in mortality as a result of changing prescribing patterns. Consequently, we cannot be fully 
confident that the changing antibiotic patterns we have seen are beneficial or not. 
 
However, we believe our findings are robust and already leading to changes in Azerbaijan. This will 
continue. 
 
6. Conclusion 
 
There are encouraging signs regarding the utilisation of antibiotics in Azerbaijan in recent years, 
which may wellhave been facilitated by multiple educational and other activities among key 
stakeholder groups. However, further research is needed befoe we can make definitive statements. In 
the meantime, these activities are continuing to help to improve the appropriate use of antibiotics in 
Azerbaijn, alongside looking more critically at diagnoses.  
 
There are some concerns, which  include the high use of ceftriaxone among the cephalosporins as 
well as the growing use of tetracyclines in recent years, and these will be the target of further 
research and activities. Monitoring the future use of antibiotics should be helped by the introduction of 
electronic prescribing, and the introduction of INN prescribing should help  reduce the influence of 
pharmaceutical companies. 
 
7. Key Issues 
 
x There have been multiple and intergrated initiatives involving all key stakeholders in Azerbaijan in 
recent years to improve antibiotic use. These initiatives have resulted in a significant reduction in 
total antibiotic use 
x Current utilisation of antibiotics in Azerbaijan in 2015 was 8.02 DIDs, the lowest among 
neigbouring countries 
x There was high use of beta lactam antibiotics over the years, in line with WHO and ECDC 
guidance; however, growing use of tetracyclines in 2015 at the expense of the penicillins as a 
result of new pricing policies is a concern 
x Overall low use of cephalosporins (although high use of third generation cephalosporins up to 
85% of total cephalosporins), macrolides and quinolones in recent years is encouraging, 
especially when compared to neighbouring countries 
x Future initiatives are targeting the use of third generation cephalosporins as well as any remaining 
self-purchasing of antibiotics. INN and electronic prescribing should help with this, as well as 
further improve the quality of antibiotic prescribing in Azerbaijan in the future   
x The findings suggest that multiple initiatives can improve physician prescribing, in accordance 
with other published studies 
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